39 stories mentioning MRK
Every FINWIRES story that references MRK, newest first.
Merck & Co (MRK) has an average rating of overweight and mean price target of $132.13, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $112.57, Change: $+3.39, Percent Change: +3.10%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target price at $135, 13.4x our 2027 EPS estimate, a discount to MRK's 10-year historical forward P/E average. We maintain our 2026 EPS estimate at $5.14 and our 2027 EPS view at $10.06. MRK reported a solid Q1 for 2026, characterized by top-line revenue growth and significant progress in its pipeline and portfolio transformation. Total revenues reached $16.3 billion (+5% Y/Y) due to continued strength in the Oncology and Animal Health divisions, alongside growing contributions from new product launches. The company is actively executing a successful strategy of diversifying its growth drivers beyond its flagship drug, KEYTRUDA, through both internal and external development.We think the Terns acquisition, expected to close during Q2, will further strengthen MRK's hematology pipeline with TERN-701 for chronic myeloid leukemia asset, demonstrating continued external innovation efforts in the company's strategic transformation journey.
Health care stocks were rising premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1% higher and the iShares Biotechnology ETF (IBB) up 0.6%.Eli Lilly (LLY) shares were up more than 5% after the company reported higher Q1 non-GAAP earnings and revenue, and raised its 2026 outlook.Merck (MRK) stock was down more than 1% after the company said it swung to a Q1 adjusted loss.Alnylam Pharmaceuticals (ALNY) shares were up more than 2% after the company posted higher Q1 adjusted net income and revenue.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Merck reported Q1 2026 sales of $16.3B, up 5% Y/Y and $440M above consensus, due to pharmaceutical segment growth of 5% Y/Y to $14.3B and robust Animal Health performance (+13% Y/Y to $1.8B). Non-GAAP loss per share of $1.28 vs. $2.22 earnings in Q1 2025, yet beat the consensus by $0.19, reflecting a $9.0B ($3.62/share) Cidara acquisition charge. We view the continued commercial momentum as supportive of MRK's strategic transformation, with KEYTRUDA delivering $8.0B in sales (+12% Y/Y) across broad-based indications and WINREVAIR revenues nearly doubling to $525M with accelerating U.S. uptake and international expansion. Management raised 2026 sales guidance to $65.8B-$67.0B from $65.5B-$67.0B and lifted non-GAAP EPS to $5.04-$5.16 from $5.00-$5.15, including FX benefits. We think the pending $6.7B Terns acquisition will further strengthen MRK's hematology pipeline with TERN-701, demonstrating continued external innovation efforts in the company's portfolio diversification strategy.
US equity markets were mostly pointing higher before the opening bell Thursday as investors digest the latest financial results from some of the biggest technology companies and await a key inflation report.The S&P 500 rose 0.1% and the Nasdaq added 0.2% in premarket activity, while the Dow Jones Industrial Average declined 0.2%. The indexes finished the previous trading session mixed.Shares of Meta Platforms (META) fell 8.8% pre-bell after the Facebook parent lifted its full-year capital expenditure guidance mainly due to higher component pricing, even though it reported stronger-than-expected first-quarter results. Microsoft (MSFT) decreased 1.8% as the tech giant said its capital expenditures will be about $190 billion in 2026, while its fiscal third-quarter results topped market estimates."It's crystal clear to us that the (artificial intelligence) revolution is accelerating at a warp speed pace with 2026 being an inflection point year for AI with hyperscalers now investing over $700 billion in (capital expenditures) in (2026) to capitalize on the opportunities in the space," Wedbush Securities said in a Thursday client note.Alphabet's (GOOG, GOOGL) class A and C shares climbed more than 6% each amid upbeat first-quarter results. Amazon (AMZN) inclined 2.5% as the e-commerce giant issued a strong second-quarter revenue outlook.iPhone maker Apple (AAPL) is scheduled to release its quarterly earnings after the markets close. Eli Lilly (LLY), Mastercard (MA), Caterpillar (CAT), Merck (MRK), Royal Caribbean Cruises (RCL) and Hershey (HSY) are slated to announce their results before the bell, among others.The personal income and outlays report for March is due to be released at 8:30 am ET. The report includes the personal consumption expenditure core price index, the Federal Reserve's preferred inflation metric.The central bank's Federal Open Market Committee left its benchmark interest rate unchanged on Wednesday as policymakers saw the Middle East conflict fueling uncertainty around the US economic outlook. In a post-meeting press conference, Jerome Powell said he will stay on as a Fed governor for an indefinite period after his term as Fed chief expires on May 15.The US Senate Banking Committee on Wednesday voted to advance Kevin Warsh's nomination as Fed chair to the Republican-controlled Senate.Treasury yields were down in premarket action, with the two-year rate retreating 3.2 basis points to 3.9% and the 10-year rate off 1.8 basis points to 4.4%.President Donald Trump is expected to receive a briefing on fresh potential military options against Iran on Thursday, Axios reported, citing two sources with knowledge. Trump recently told the news outlet that he will maintain the US naval blockade of Iranian ports until Tehran agrees to a nuclear deal.West Texas Intermediate crude oil slipped 0.2% to $106.62 a barrel before the open, while Brent decreased 1.6% to $116.20.Thursday's economic calendar also has the initial estimate report for the first-quarter gross domestic product at 8:30 am, along with the weekly jobless claims bulletin. The Chicago purchasing managers' index for April posts at 9:45 am.Gold rose 1.8% to $4,642 per troy ounce, while bitcoin moved 0.7% higher to $75,974.
Terns Pharmaceuticals (TERN) said Monday the US Food and Drug Administration has granted breakthrough therapy designation to TERN-701 for the treatment of certain adult patients with chronic myeloid leukemia.The designation is for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase without the T315I mutation previously treated with two or more tyrosine kinase inhibitors, Terns said.The label is intended to expedite the development and review of potential new medicines for serious conditions or address significant unmet medical needs, it said.Merck agreed in March to buy Terns for $53 per share, or about $6.7 billion.Price: $52.91, Change: $+0.02, Percent Change: +0.03%
Health care stocks were mixed late Wednesday afternoon, with the NYSE Health Care Index down 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.1%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, Biogen (BIIB) shares rose 2.2% after UBS upgraded the biotechnology company's stock to buy from neutral and boosted its price target to $225 per share from $185.Boston Scientific (BSX) shares jumped 8.3% after the company reported Q1 results exceeded Wall Street's estimates.Intuitive Surgical (ISRG) shares climbed 7% after the company lifted the full-year procedure growth outlook of its Da Vinci robotic surgery system and reported better-than-expected Q1 results.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that may be valued at more than $8 billion, Reuters reported. Merck shares rose 0.4%, and Inhibrx surged 35%.
Health care stocks edged up Wednesday afternoon with the NYSE Health Care Index little changed, paring earlier gains, and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.2%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, Boston Scientific (BSX) shares jumped 9.1% after the company reported Q1 results exceeded Wall Street's estimates.Intuitive Surgical (ISRG) shares climbed 7.7% after the company lifted the full-year procedure growth outlook of its Da Vinci robotic surgery system and reported better-than-expected Q1 results.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that may be valued at more than $8 billion, Reuters reported. Merck shares rose 0.2%, and Inhibrx surged 42%.
All three major US stock indexes were up in late-morning trading Wednesday following reports of Iranian attacks on vessels in the Strait of Hormuz and President Donald Trump's extension of the ceasefire between the warring nations.In company news, GE Vernova (GEV) reported Q1 earnings Wednesday of $17.44 per share, up from $0.91 a year earlier. Total Q1 revenue was $9.34 billion, up from $8.03 billion a year ago and above the FactSet consensus analyst estimate of $9.25 billion. For 2026, the company said it expects revenue of about $44.5 billion to $45.5 billion, up from its previous outlook of $44 billion to $45 billion and compared to the FactSet consensus of $44.66 billion. GE Vernova shares were up 12.4% around midday.Vertiv (VRT) reported Q1 adjusted earnings Wednesday of $1.17 per diluted share, up from $0.64 a year earlier and above the FactSet consensus of $1.00. First-quarter revenue was $2.65 billion, up from $2.04 billion a year ago and above the FactSet consensus of $2.64 billion. For Q2, the company said it expects adjusted EPS of $1.37 to $1.43 on revenue of $3.25 billion to $3.45 billion. Analysts polled by FactSet expect $1.43 and $3.40 billion, respectively. For full-year 2026, Vertiv said it expects adjusted EPS of $6.30 to $6.40, up from its previous outlook of $5.97 to $6.07 and above the FactSet consensus of $6.12. Vertiv expects full-year revenue to be $13.50 billion to $14.00 billion, up from its previous guidance of $13.25 billion to $13.75 billion and compared to the FactSet consensus of $13.63 billion. Vertiv shares were down 2.6%.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at over $8 billion, Reuters reported Wednesday, citing people familiar with the matter. Merck shares were down 0.2%, while Inhibrx shares were up 31.9%.Boeing (BA) reported a Q1 core loss Wednesday of $0.20 per share, narrowing from a loss of $0.49 a year earlier and compared to the FactSet consensus estimate of a loss of $0.68. First-quarter revenue was $22.22 billion, up from $19.50 billion a year ago and above the FactSet consensus of $21.85 billion. Cash outflow for the quarter was $1.45 billion, narrowing from $2.29 billion a year ago, and the company said Q1 deliveries increased 10% to 143 planes. Boeing shares were up 5.4%.Alphabet's (GOOG, GOOGL) Google Cloud is launching a $750 million fund to help consulting firms like Accenture (ACN), McKinsey and Deloitte get their clients to use agentic AI software, Bloomberg reported Wednesday, citing an emailed statement and an interview with a company official. Alphabet's Class C and Class A shares were up 1.5% and 1.6%, respectively. Accenture shares were down 1.9%.Philip Morris International (PM) reported Q1 adjusted earnings Wednesday of $1.96 per diluted share, up from $1.69 a year earlier and above the FactSet consensus of $1.83. Net Q1 revenue was $10.15 billion, up from $9.30 billion ay ear ago and above the FactSet consensus of $9.91 billion. For Q2, Philip Morris said it expects adjusted EPS of $2.02 to $2.07, below the FactSet consensus of $2.12. For full-year 2026, the company said it expects adjusted EPS of $8.36 to $8.51, compared to the FactSet consensus of $8.38. Philip Morris shares were up 7%.Boston Scientific (BSX) reported Q1 adjusted earnings Wednesday of $0.80 per share, up from $0.75 a year earlier and above the FactSet consensus of $0.79. First-quarter net sales were $5.20 billion, up from $4.66 billion a year ago and above the FactSet consensus of $5.17 billion. For Q2, Boston Scientific said it expects adjusted EPS of $0.82 to $0.84 and net sales growth of 5.5% to 7.5%. Analysts polled by FactSet expect adjusted EPS of $0.86. For full-year 2026, the company said it expects adjusted EPS of $3.34 to $3.41, down from its prior outlook of $3.43 to $3.49 and below the FactSet consensus of $3.45. Full-year net sales are now expected to grow about 7.0% to 8.5%, down from the company's previous guidance of 10.5% to 11.5% growth. Shares of the company were up 8.4%.AT&T (T) reported Q1 earnings Wednesday of $0.54 per diluted share, down from $0.61 a year earlier and below the FactSet consensus of $0.55. First-quarter operating revenue was $31.51 billion, up from $30.63 billion a year ago and above the FactSet consensus of $31.25 billion. AT&T shares were down 1.8%.Price: $1119.35, Change: $+128.05, Percent Change: +12.92%
(Updates with Merck's response to a request for comment from.)Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at more than $8 billion, Reuters reported Wednesday, citing people familiar with the matter.Inhibrx is exploring a joint spin-off of the treatment, INBRX-106, as well as a second experimental cancer drug, which could have a combined value of more than $9 billion if clinical trials succeed, the people told Reuters.Inhibrx and Merck declined to comment to, while Ono Pharmaceutical didn't immediately reply to a request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $112.63, Change: $+0.07, Percent Change: +0.06%
(Updates with Inhibrx response to a request for comment from.)Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at more than $8 billion, Reuters reported Wednesday, citing people familiar with the matter.Inhibrx is exploring a joint spin-off of the treatment, INBRX-106, as well as a second experimental cancer drug, which could have a combined value of more than $9 billion if clinical trials succeed, the people told Reuters.Inhibrx declined to comment to, while Merck and Ono Pharmaceutical didn't immediately reply to requests for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $112.88, Change: $+0.32, Percent Change: +0.28%
Health care stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) 0.3% higher.Boston Scientific (BSX) shares were up more than 5% after the company reported higher Q1 adjusted earnings and net sales.Merck (MRK), Germany's Merck KGaA and Japan's Ono Pharmaceutical have expressed interest in Inhibrx Biosciences' (INBX) experimental cancer medicine that could be valued at more than $8 billion, Reuters reported, citing people familiar with the matter. Inhibrx Biosciences stock was up more than 48% pre-bell.Healthcare Services Group (HCSG) shares were up more than 22% after the company reported higher Q1 earnings and revenue.
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) decreased 1%.In corporate news, Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a randomized study to support approval of its experimental treatment PBFT02, a move that adds time, cost, and uncertainty, Wedbush said Tuesday in a report. Wedbush downgraded Passage Bio's stock to neutral from outperform and cut its price target to $8 from $32. Passage Bio shares dropped 2.9%.Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.7%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 7%.Quest Diagnostics (DGX) shares popped more than 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.
Merck (MRK) said Tuesday the US Food and Drug Administration approved the Idvynso drug regimen to treat HIV-1 infection in adults.Phase 3 trial data supported the approval of Idvynso, according to a statement.Price: $112.60, Change: $-4.51, Percent Change: -3.85%
Arcus Biosciences (RCUS) shares have a favorable setup following Merck's (MRK) belzutifan phase 3 failure in Litespark-012, with Wedbush Securities saying the readout does not represent negative readthrough for Arcus' casdatifan and highlights a differentiated profile in clear cell renal cell carcinoma, or RCC.The brokerage said in a Tuesday note that the Merck data do not impact Arcus' TKI-free frontline strategy and that casdatifan remains supported by a more optimal development approach and stronger comparative efficacy versus belzutifan.Wedbush also said recent weakness following the discontinuation of Arcus' domvanalimab program has created an attractive entry point ahead of upcoming clinical data readouts, reinforcing a favorable setup for the stock.The firm reiterated its outperform rating on the stock and price target of $41 per share.Price: $23.31, Change: $+0.57, Percent Change: +2.51%
Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) decreased 0.7%.In corporate news, Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.9%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 8%.Quest Diagnostics (DGX) shares popped 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.
Merck (MRK) has an average rating of overweight and mean price target of $130.88, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $112.78, Change: $-4.32, Percent Change: -3.69%
Health care stocks climbed late Friday afternoon, with the NYSE Health Care Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) gained 1.6%.In corporate news, Abbott Laboratories' (ABT) end-markets remain healthy despite a lower 2026 organic revenue guidance amid fiscal Q1 challenges and mixed performance, RBC Capital Markets said in a note. Abbott shares rose 1.7%.Merck (MRK) shares added 2.8% after it said Friday that the European Commission has approved Enflonsia to prevent respiratory tract disease in newborns and infants.Kura Oncology (KURA) shares jumped past 9% after it said Friday that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.Psyence Biomedical (PBM) shares surged 30% after it acknowledged recent reports saying that the US administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder, addiction, and other serious neurological and mental health conditions. Through its investment in PsyLabs, Psyence has established a position in the manufacturing of ibogaine and ibogaine derivatives, it said.
Health care stocks climbed Friday afternoon, with the NYSE Health Care Index rising 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) advanced 1.4%.In corporate news, Merck (MRK) shares rose 2.3% after it said Friday that the European Commission has approved Enflonsia to prevent respiratory tract disease in newborns and infants.Kura Oncology (KURA) shares jumped nearly 7% after it said Friday that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.Psyence Biomedical (PBM) shares surged 66% after it acknowledged recent reports saying that the US administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder, addiction, and other serious neurological and mental health conditions. Through its investment in PsyLabs, Psyence has established a position in the manufacturing of ibogaine and ibogaine derivatives, it said.
Showing 21-39 of 39